Zhang X, Zhang Z, Zhao Y, Jiang N, Qiu J, Yang Y, Li J, Liang X, Wang X, Tse G, Li G, Liu T (2017) Alogliptin, a dipeptidyl peptidase-4 inhibitor, alleviates atrial remodeling and improves mitochondrial function and biogenesis in diabetic rabbits
Federal rules around compounding can change depending on drug availability, patient-specific medical need, pharmacy type, and FDA enforcement priorities
Higher doses should be administered only with caution and only where clinical and biochemical considerations make it seem likely that higher doses will be benefit
For a deeper discussion of the cancer concern, see Can Wegovy Cause Cancer